Indication of prophylactic vaccines as a tool for secondary prevention in HPV-linked disease
To determine whether quadrivalent HPV vaccination is effective in reducing recurrent disease in women with a previous history of HPV disease.
All women under 45 years of age treated for HPV-linked disease and with negative HPV test, cytology and colposcopy 3 months after treatment were enrolled. Women were randomly assigned into two groups: a group that received HPV vaccine post treatment and a group that was only submitted to follow-up. Follow-up was performed every 6 months for a duration of at least 3 years. Kaplan–Meier curve was used to estimate the overall disease-free survival during the follow-up period. Statistical analysis was performed by Fisher’s exact test.
From November 2013 to October 2014, we enrolled a total of 178 women at Careggi University Hospital in Florence and at Azienda USL in Massa Carrara. 12 out of 89 patients in the non-vaccination group recurred (13.5%), while 3 out of 89 patients in the vaccination group recurred (3.4%). The Kaplan–Meier curves showed a statistically difference in the log rank test (p = 0.0147) for the overall disease-free survival in the study groups during follow-up. The rate of recurrence was significantly higher in the non-vaccination group, with a p = 0.0279 by Fisher exact test.
The introduction of anti-HPV vaccination during the follow-up post treatment for HPV-linked disease is recommended to reduce the risk of recurrence. The clinical implication of this could be very important to influence post-treatment management of HPV disease.
KeywordsHPV vaccination Squamous intraepithelial lesion HPV Secondary prevention
Protocol/project development: AP, AG, MF. Conceptualization: AP. Funding acquisition: CB, MF. Data collection and management: CB, NA. Blind colposcopists and physicians: AP, AG, MGF. Blind biologists: CB. Data Analysis: CB, NZ. Manuscript writing/editing: CB, NA, GC, FP. Supervision: GC, FP.
This was funded by research grants of Fondazione Cassa di Risparmio di Florence
Compliance with ethical standards
Conflict of interest
We declare that we have no conflict of interest.
- 7.Ault KA, Future II Study Group (2007) Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet 369:1861–1868CrossRefGoogle Scholar
- 11.Garland SM, Paavonen J, Jaisamrarn U, HPV PATRICIA Study Group et al (2016) Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high-grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer 139(12):2812–2826CrossRefGoogle Scholar
- 19.Pieralli A, Corioni S, Bianchi C et al. Feasibility of Quadrivalent HPV Vaccination as Immunologic Booster to Prevent Relapses In an Italian Cohort of Women Treated for Cervical Intraepithelial Neoplasia (CIN). MOJ Womens Health 2(4): 00040. https://doi.org/10.15406/mojwh.2016.02.00040